The role of arginine vasopressin and its receptors in the normal and failing rat heart

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 5, 2003, Pages 495-504

  Chandrashekhar, Y ^a   Prahash, Arun J ^a   Sen, Soma ^a   Gupta, Sudhir ^a   Roy, Sabita ^a   Anand, Inder S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AVP; Cardiomyocytes; Heart failure; Receptors; Ventricular remodeling

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; AK 3 30; ANGIOTENSIN; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; MESSENGER RNA; NEUROHORMONE; NORADRENALIN; PHOSPHORUS ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CALCIUM CELL LEVEL; CELL FUNCTION; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HORMONE ACTION; LIGAND BINDING; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037623413     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00053-1     Document Type: Article

References (30)

1. Laszlo F.A., Laszlo Jr F., De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 43:1991;73-108.
2. Naitoh M., Suzuki H., Murakami M., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 267:1994;H2245-2254.
3. Goldsmith S.R., Francis G., Cowley Jr A.W., et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1:1983;1385-1390.
4. Maolic J.M., Bauters C., Himbert D., et al. Phenylephrine, vasopressin and angiotensin II as determinants of proto oncogene and heat shock protein gene expression in adult rat heart and aorta. J Hypertens. 7:1989;195-201.
5. Hupf H., Grimm D., Riegger G.A.J., et al. Evidence for a vasopressin system in the heart. Circ Res. 84:1999;365-370.
6. Anand I.S., Liu D., Chugh S.S., Prahash A.J., Gupta S., John R., et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation. 96:1997;3974-3984.
7. Okuda H., Suzuki H., Kanno Y., et al. Chronic and selective vasopressin blockade in spontaneously hypertensive rats. Am J Physiol. 267:1994;R1467-1471.
8. Yamamura Y., Ogawa H., Chihara T., et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 26:(252):1991;572-574.
9. Prahash A.J., Gupta S., Anand I.S. Myocyte response to beta-adrenergic stimulation is preserved in the noninfarcted myocardium of globally dysfunctional rat hearts after myocardial infarction. Circulation. 102:2000;1840-1846.
10. Gupta S., Prahash A.J., Anand I.S. Myocyte contractile function is intact in the post-infarct remodeled rat heart despite molecular alterations. Cardiovasc Res. 48:2000;77-88.
11. Chandrashekhar Y., Prahash A.J., Sen S., et al. Cardiomyocyte contractile dysfunction does not explain global left ventricular dysfunction following ischemia-reperfusion. J Am Coll Cardiol. 34:1999;594-602.
12. Mann D.L., Kent R.L., Parsons B., et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 85:1992;790-804.
13. i in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptor. Circ Res. 69:1991;239-245.
14. Walker B.R., Childs M.E., Adams E.M. Direct cardiac effects of vasopressin: role of V1 and V2 vasopressinergic receptors. Am J Physiol. 255:1988;H261-265.
15. Wilson M.F., Brackett D.J., Archer L.T., et al. Mechanisms of impaired cardiacfunction by vasopressin. Ann Surg. 191:1980;494-500.
16. Maturi M.F., Martin S.E., Markle D., et al. Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of non-diseased vessels. Circulation. 83:1991;2111-2121.
17. Cowley Jr A.W., Monos E., Guyton A.C. Interaction of vasopressin and the baroreceptor reflex system in the regulation of blood pressure in the dog. Circ Res. 34:1974;505-514.
18. 2+ concentration in vascular and cardiac myocytes. Hypertension. 9:1992;730-733.
19. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 20:1992;248-254.
20. Gavras H. Role of vasopressin in clinical hypertension and congestive heart failure: interaction with the sympathetic nervous system. Clin Chem. 37:1991;1828-1830.
21. Raya T., Gay R.G., Goldman S. Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilation. J Pharmacol Exp Ther. 255:1990;1015-1020.
22. Stone C.K., Liang C.S., Imai N., et al. Short term hemodynamic effects of vasopressin V1 receptor inhibition in chronic right sided congestive heart failure. Circulation. 78:1988;1251-1259.
23. Mulinari R.A., Gavras I., Wang Y.X., et al. Effects of a vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction. Circulation. 81:1990;308-311.
24. Charles C.J., Donald R.A., Ikram H., et al. Arginine vasopressin V1-receptor antagonism in an ovine model of acute myocardial infarction. J Cardiovasc Pharmacol. 32:(5):1998;777-782.
25. Yatsu T., Tomura Y., Tahara A., et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 376:1999;239-246.
26. Nishikimi T., Kawano Y., Saito Y., et al. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol. 27:1996;275-282.
27. Wang Y., Franco I., Gavras I., et al. Effect of chronic administration of a vasopressin antagonist with combined antivasopressor and antidiuretic activities in rats with left ventricular dysfunction. J Lab Clin M. 117:1991;313-318.
28. Fujita H., Yoshiyama M., Takeuchi K., et al. The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats. Japn. J Pharmacol. 78:1998;229-232.
29. Clair M.J., King M.K., Goldberg A.T., et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther. 293:2000;852-860.
30. Burrell L.M., Phillips P.A., Risvanis J., et al. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in heart failure in the rat. Am J Physiol. 275:1998;H176-H182.